ATE383858T1 - Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen - Google Patents

Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen

Info

Publication number
ATE383858T1
ATE383858T1 AT02730462T AT02730462T ATE383858T1 AT E383858 T1 ATE383858 T1 AT E383858T1 AT 02730462 T AT02730462 T AT 02730462T AT 02730462 T AT02730462 T AT 02730462T AT E383858 T1 ATE383858 T1 AT E383858T1
Authority
AT
Austria
Prior art keywords
sup
sub
compounds
linkage
oxides
Prior art date
Application number
AT02730462T
Other languages
German (de)
English (en)
Inventor
Garry Fenton
Neil Victor Harris
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0113708A external-priority patent/GB0113708D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of ATE383858T1 publication Critical patent/ATE383858T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02730462T 2001-06-06 2002-06-05 Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen ATE383858T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0113708A GB0113708D0 (en) 2001-06-06 2001-06-06 Chemical compounds
US31150201P 2001-08-10 2001-08-10

Publications (1)

Publication Number Publication Date
ATE383858T1 true ATE383858T1 (de) 2008-02-15

Family

ID=26246159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02730462T ATE383858T1 (de) 2001-06-06 2002-06-05 Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen

Country Status (13)

Country Link
US (1) US7211586B2 (https=)
EP (1) EP1392306B1 (https=)
JP (1) JP4583751B2 (https=)
AT (1) ATE383858T1 (https=)
AU (1) AU2002302783B2 (https=)
CA (1) CA2449402C (https=)
DE (1) DE60224664T2 (https=)
DK (1) DK1392306T3 (https=)
ES (1) ES2296926T3 (https=)
IL (1) IL159203A0 (https=)
MX (1) MXPA03009660A (https=)
PT (1) PT1392306E (https=)
WO (1) WO2002098426A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
GEP20084439B (en) 2004-01-23 2008-07-25 Amgen Inc Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd 2−アリールアミノベンゾオキサゾール誘導体
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
WO2007050124A1 (en) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
WO2009128934A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
AU2012322095B2 (en) * 2011-10-14 2017-06-29 Ambit Biosciences Corporation Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases
WO2013082000A1 (en) * 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
US20190389836A1 (en) * 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
WO2023287241A1 (ko) * 2021-07-15 2023-01-19 주식회사 휴사이온 신규한 벤즈옥사졸아민 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑hdac6抑制劑及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
SK20052000A3 (sk) * 1998-06-30 2002-08-06 Pfizer Products Inc. Nepeptidové inhibítory VLA-4 dependentnej bunkovej väzby použiteľné pri liečení zápalových, autoimunitných a respiračných chorôb
US6608084B1 (en) * 1998-08-26 2003-08-19 Aventis Pharma Ltd. Aza-bicycles which modulate the inhibition of cell adhesion
ES2288871T3 (es) * 1999-09-24 2008-02-01 Genentech, Inc. Derivados de tirosina.

Also Published As

Publication number Publication date
US7211586B2 (en) 2007-05-01
MXPA03009660A (es) 2004-04-02
PT1392306E (pt) 2008-03-07
DK1392306T3 (da) 2008-05-19
AU2002302783B2 (en) 2006-11-16
JP2005500276A (ja) 2005-01-06
WO2002098426A1 (en) 2002-12-12
CA2449402C (en) 2009-08-11
EP1392306A1 (en) 2004-03-03
EP1392306B1 (en) 2008-01-16
US20040122047A1 (en) 2004-06-24
DE60224664T2 (de) 2009-01-08
CA2449402A1 (en) 2002-12-12
IL159203A0 (en) 2004-06-01
JP4583751B2 (ja) 2010-11-17
ES2296926T3 (es) 2008-05-01
DE60224664D1 (de) 2008-03-06

Similar Documents

Publication Publication Date Title
ATE383858T1 (de) Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP0385850A3 (fr) Nouveaux dérivés de benzimidazoles et azabenzimidazoles, leurs procédés de préparation, intermédiaires de synthèse, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et les ulcères duodénaux
EE200100528A (et) Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine
DE60131160D1 (de) Caspase-inhibitoren und ihre verwendungen
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
DE69120500D1 (de) Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
ATE211468T1 (de) Neuraminsäuredervate, ihre herstellung und medizinische verwendung
ATE324890T1 (de) Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
ATE337318T1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
TR199902350T2 (xx) Yeni piridin t�revleri ve onlardan olu�an farmakotik bile�imler.
ATE258050T1 (de) Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
DK0835868T3 (da) 2-aryl-3-aminoaryloxynaphthylforbindelser, mellemprodukter, sammensætninger og fremgangsmåder
BR0009582A (pt) Composto, composição farmacêutica, e, processopara o tratamento de uma condição de doençaselecionada de artrite reumatóide, doença dealzheimer, câncer, esquizofrenia, edema, rinitealérgica, inflamação, dor, hipermobilidadegastrointestinal , asma gástrica, refluxogastroesfageal, ansiedade, emese, doença dehuntington, psicoses incluindo depressão,hipertensão, enxaqueca e urticária
DE69918431D1 (de) Benzofuroxanderivate und ihre verwendung zur behandlung von angina pectoris
TR200002808T2 (tr) İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri
FR2655043B1 (fr) Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
TR200102639T2 (tr) Yeni morfolin türevleri, bunları hazırlamak için proses ve bunları içeren farmasötik kompozisyonlar.
NO992316L (no) Benzensulfonamidderivater og legemidler inneholdende disse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392306

Country of ref document: EP

REN Ceased due to non-payment of the annual fee